Sirtuin 1 Deacetylase. A Key Regulator of Hepatic Lipid Metabolism.

Vitamins and Hormones

Volumn 91, Issue , 2013, Pages 385-404

  Kemper, Jongsook Kim ^a   Choi, Sung E ^a   Kim, Dong Hyun ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Fatty liver; Lipogenesis; Obesity; SIRT1; SREBP 1c; Oxidation

Indexed keywords

EID: 84873868477     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407766-9.00016-X     Document Type: Chapter

References (81)

1. Baker R.G., Hayden M.S., Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metabolism 2011, 13:11-22.
2. Banks A.S., Kon N., Knight C., Matsumoto M., Gutierrez-Juarez R., Rossetti L., et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metabolism 2008, 8:333-341.
3. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
4. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
5. Brown M.S., Goldstein J.L. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89:331-340.
6. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
7. Canto C., Auwerx J. Caloric restriction, SIRT1 and longevity. Trends in Endocrinology and Metabolism 2009, 20:325-331.
8. Canto C., Auwerx J. Targeting sirtuin 1 to improve metabolism: All you need is NAD(+)?. Pharmacological Reviews 2012, 64:166-187.
9. Canto C., Gerhart-Hines Z., Feige J.N., Lagouge M., Noriega L., Milne J.C., et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
10. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011, 6:e23937.
11. Chalkiadaki A., Guarente L. Metabolic signals regulate SIRT1 expression. EMBO Reports 2011, 12:985-986.
12. Chalkiadaki A., Guarente L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nature Reviews. Endocrinology 2012, 8:287-296.
13. Chen D., Bruno J., Easlon E., Lin S.J., Cheng H.L., Alt F.W., et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes & Development 2008, 22:1753-1757.
14. Chen G., Liang G., Ou J., Goldstein J.L., Brown M.S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:11245-11250.
15. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48:1810-1820.
16. Chiang J.Y. Bile acids: Regulation of synthesis. Journal of Lipid Research 2009, 50:1955-1966.
17. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: Old questions and new insights. Science 2011, 332:1519-1523.
18. Coste A., Louet J.F., Lagouge M., Lerin C., Antal M.C., Meziane H., et al. The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{Alpha}. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17187-17192.
19. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., et al. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metabolism 2006, 3:87-98.
20. Escande C., Chini C.C., Nin V., Dykhouse K.M., Novak C.M., Levine J., et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. The Journal of Clinical Investigation 2010, 120:545-558.
21. Evans R.M., Barish G.D., Wang Y.X. PPARs and the complex journey to obesity. Nature Medicine 2004, 10:355-361.
22. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metabolism 2008, 8:347-358.
23. Finkel T. Ageing: A toast to long life. Nature 2003, 425:132-133.
24. Gottlieb S., Esposito R.E. A new role for a yeast transcriptional silencer gene, SIR2, in regulation of recombination in ribosomal DNA. Cell 1989, 56:771-776.
25. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
26. Guarente L. Sirtuins in aging and disease. Cold Spring Harbor Symposia on Quantitative Biology 2007, 72:483-488.
27. Haigis M.C., Sinclair D.A. Mammalian Sirtuins: Biological insights and disease relevance. Annual Review of Pathology 2010, 5:253-295.
28. Horton J.D. Sterol regulatory element-binding proteins: Transcriptional activators of lipid synthesis. Biochemical Society Transactions 2002, 30:1091-1095.
29. Horton J.D., Bashmakov Y., Shimomura I., Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:5987-5992.
30. Houtkooper R.H., Pirinen E., Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nature Reviews. Molecular Cell Biology 2012, 13:225-238.
31. Hylemon P.B., Zhou H., Pandak W.M., Ren S., Gil G., Dent P. Bile acids as regulatory molecules. Journal of Lipid Research 2009, 50:1509-1520.
32. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
33. Kaeberlein M., McVey M., Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes & Development 1999, 13:2570-2580.
34. Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 2005, 1:15-25.
35. Kalaany N.Y., Mangelsdorf D.J. LXRS and FXR: The yin and yang of cholesterol and fat metabolism. Annual Review of Physiology 2006, 68:159-191.
36. Kemper J.K. Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. Biochimica et Biophysica Acta 2011, 1812:842-850.
37. Kemper J.K., Xiao Z., Ponugoti B., Miao J., Fang S., Kanamaluru D., et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metabolism 2009, 10:392-404.
38. Klar A.J., Fogel S., Macleod K. MAR1-A regulator of the HMa and HMalpha loci in Saccharomyces cerevisiae. Genetics 1979, 93:37-50.
39. Kwon H.S., Ott M. The ups and downs of SIRT1. Trends in Biochemical Sciences 2008, 33:517-525.
40. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
41. Lee J., Kemper J.K. Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging (Albany NY) 2010, 2:527-534.
42. Lee F.Y., Lee H., Hubbert M.L., Edwards P.A., Zhang Y. FXR, a multipurpose nuclear receptor. Trends in Biochemical Sciences 2006, 31:572-580.
43. Lee J., Padhye A., Sharma A., Song G., Miao J., Mo Y.Y., et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic Sirtuin 1 levels via microRNA-34a inhibition. The Journal of Biological Chemistry 2010, 285:12604-12611.
44. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews 2009, 89:147-191.
45. Li X., Zhang S., Blander G., Tse J.G., Krieger M., Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Molecular Cell 2007, 28:91-106.
46. Liu Y., Dentin R., Chen D., Hedrick S., Ravnskjaer K., Schenk S., et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008, 456:269-273.
47. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
48. Meshkani R., Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clinical Biochemistry 2009, 42:1331-1346.
49. Neilson J.R., Sharp P.A. Small RNA regulators of gene expression. Cell 2008, 134:899-902.
50. Noriega L.G., Feige J.N., Canto C., Yamamoto H., Yu J., Herman M.A., et al. CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Reports 2011, 12:1069-1076.
51. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschop M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9793-9798.
52. Ponugoti B., Kim D.H., Xiao Z., Smith Z., Miao J., Zang M., et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. The Journal of Biological Chemistry 2010, 285:33959-33970.
53. Purushotham A., Schug T.T., Xu Q., Surapureddi S., Guo X., Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metabolism 2009, 9:327-338.
54. Purushotham A., Xu Q., Lu J., Foley J.F., Yan X., Kim D.H., et al. Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1alpha/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice. Molecular and Cellular Biology 2012, 32:1226-1236.
55. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., et al. Regulation of mouse sterol regulatory element-binding protein-1c Gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes & Development 2000, 14:2819-2830.
56. Rodgers J.T., Lerin C., Gerhart-Hines Z., Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Letters 2008, 582:46-53.
57. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
58. Rodgers J.T., Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12861-12866.
59. Russell D.W. Nuclear orphan receptors control cholesterol catabolism. Cell 1999, 97:539-542.
60. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annual Review of Biochemistry 2003, 72:137-174.
61. Russell J.C., Proctor S.D. Small animal models of cardiovascular disease: Tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovascular Pathology 2006, 15:318-330.
62. Russell D.W., Setchell K.D.R. Bile acid biosynthesis. Biochemistry (NY) 1992, 31:4737-4749.
63. Shimano H., Horton J.D., Shimomura I., Hammer R.E., Brown M.S., Goldstein J.L. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. The Journal of Clinical Investigation 1997, 99:846-854.
64. Sinclair D.A., Guarente L. Extrachromosomal rDNA circles-A cause of aging in yeast. Cell 1997, 91:1033-1042.
65. Sinclair D.A., Lin S.J., Guarente L. Life-span extension in yeast. Science 2006, 312:195-197. author reply 195-197.
66. Stefan N., Kantartzis K., Haring H.U. Causes and metabolic consequences of fatty liver. Endocrine Reviews 2008, 29:939-960.
67. Tanoli T., Yue P., Yablonskiy D., Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: Roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. Journal of Lipid Research 2004, 45:941-947.
68. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism 2011, 14:612-622.
69. Tissenbaum H.A., Guarente L. Increased dosage of a Sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
70. Tontonoz P., Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Molecular Endocrinology 2003, 17:985-993.
71. Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011, 474:649-653.
72. Uyeda K., Repa J.J. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metabolism 2006, 4:107-110.
73. Walker A.K., Yang F., Jiang K., Ji J.Y., Watts J.L., Purushotham A., et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes & Development 2010, 24:1403-1417.
74. Wang R.H., Kim H.S., Xiao C., Xu X., Gavrilova O., Deng C.X. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. The Journal of Clinical Investigation 2011, 121:4477-4490.
75. Wang R.H., Li C., Deng C.X. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. International Journal of Biological Sciences 2010, 6:682-690.
76. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. The Journal of Clinical Investigation 2004, 113:1408-1418.
77. Yamakuchi M., Ferlito M., Lowenstein C.J. MiR-34a repression of SIRT1 regulates apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:13421-13426.
78. Yamamoto H., Schoonjans K., Auwerx J. Sirtuin functions in health and disease. Molecular Endocrinology 2007, 21:1745-1755.
79. Yoshikawa T., Shimano H., Amemiya-Kudo M., Yahagi N., Hasty A.H., Matsuzaka T., et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Molecular and Cellular Biology 2001, 21:2991-3000.
80. Yoshino J., Mills K.F., Yoon M.J., Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism 2011, 14:528-536.
81. Zhang Y., Castellani L.W., Sinal C.J., Gonzalez F.J., Edwards P.A. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes & Development 2004, 18:157-169.